Who Pays

Regulatory approval opens the door, but reimbursement determines who walks through it. A therapy that is approved but not covered by insurance or national health systems remains inaccessible to the vast majority of patients. For psychedelic-assisted therapy — with its extended session times, specialized therapist requirements, and facility needs — the economics are particularly challenging.

Health technology assessment (HTA) bodies play a crucial gatekeeping role in many healthcare systems. Organizations like NICE in England, G-BA in Germany, HAS in France, and ICER in the United States evaluate whether new therapies offer sufficient value relative to their cost. These assessments typically rely on cost-effectiveness analyses that compare a therapy's outcomes (often measured in quality-adjusted life years, or QALYs) against its price and the cost of existing alternatives.

Early health economic modeling for psychedelic therapies suggests they could be cost-effective — even cost-saving — compared to standard treatments for conditions like treatment-resistant depression and PTSD. The logic is intuitive: if two or three psilocybin sessions can achieve durable remission, the long-term costs may be far lower than years of antidepressant prescriptions, therapy appointments, and the broader economic burden of untreated mental illness. But these models depend heavily on assumptions about durability of effect, retreatment rates, and the real-world cost of delivering therapy.

The pricing question is equally complex. Psychedelic-assisted therapy is expensive to deliver — a single psilocybin session might require 8+ hours of therapist time, plus preparation and integration sessions. Companies must set prices that cover these costs while remaining within the willingness-to-pay thresholds of HTA bodies and insurers. Some are exploring innovative pricing models, including outcomes-based contracts and value-based agreements.

In this section, we dive deep into the economics of psychedelic therapy implementation. We examine HTA processes across key markets, analyze the emerging cost-effectiveness evidence, explore different reimbursement models, and hear from health economists and payer representatives about what it will take to secure coverage. This is arguably the most critical — and least understood — piece of the implementation puzzle.